Immediate Chemotherapy Following Resection for High-Risk Non-Muscle-Invasive Bladder Cancer

Residual tumors after transurethral resection of bladder tumors (TURBT) range from 17-70%, and floating tumor cells from traditional segmental resection may lead to recurrence if they re-implant in the bladder wall. Immediate systemic chemotherapy post-surgery aims to eliminate microlesions promptly and minimize recurrence risk, yet its safety and efficacy require further exploration. This prospective, single-arm study delves into evaluating the efficacy and safety of immediate postoperative systemic chemotherapy in patients with suspected high-risk non-muscle-invasive bladder cancer.

Trial Details

NCT ID

NCT06889623

Phase

NA

Sponsor

Changhai Hospital

Status

RECRUITING

Cancer Type

Non-Muscle-Invasive Bladder Cancer

Interventions

• Immediate postoperative chemotherapy

Locations (sample)

• Shanghai, Shanghai Municipality, China|31.22222,121.45806

Key Eligibility Criteria

• Patients with a history and cystoscopy results indicating high-risk NMIBC:
• High-grade T1
• Any recurrent high-grade Ta
• High-grade Ta \& Tumor diameter greater than 3 cm or multifocal

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Non-Muscle-Invasive Bladder Cancer Trials on Trialify →